EGFR and non-small cell lung carcinoma: Although the use of epidermal growth factor receptor (EGFR) inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) has led to a major clinical breakthrough, eventual resistance to these inhibitors limits their further clinical benefits as happened in conventional chemotherapy [1].